Octreotide treatment increases exercise capacity in patients with acromegaly

Padayatty SJ, Perrins EJ, Belchetz PE. Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 1996:134:554–9. ISSN 0804–4643 This prospective study was conducted to determine the effect of Octreotide treatment on cardiovascular function in patients with active acromegaly. Ten acromegalic patients who failed to suppress growth hormone (GH) to < 5 mU/l during a 2 h oral glucose tolerance test were treated with 100 μg of Octreotide subcutaneously three times daily for 2 months, followed by 200 μg three times daily if the mean GH level was > 5 mU/l, for a total of 1 year. All patients had GH and insulin-like growth factor I (IGF-I) estimation, ejection fraction determined by Echocardiogram and multigated image acquisition scan, electrocardiogram (ECG), exercise ECG, 24-h ECG and chest x-ray. At 6 and 12 months, both GH and IGF-I were reduced but ECG, heart size and ejection fraction were unchanged. The patients improved symptomatically and had significant reduction in resting heart rate and increase in weight. Exercise time (mean±sd) increased from 637 ± 137s at baseline to 787 ± 101s at 1 year (p < 0.01) and work done increased from 9 ± 3.3 to 11.9 ± 2.7 metabolic equivalents (p< 0.001). We conclude that the decrease in GH and IGF-I following Octreotide treatment of acromegaly is accompanied by decreased heart rate and increased exercise capacity despite an unchanged ejection fraction. Sebastian J Padayatty, Division of Endocrinology, Baylor College of Medicine, One Baylor Plaza, Room 537E, Houston TX 77030, USA